In developing new digital therapeutics, how should Pear Therapeutics weigh the potential for higher efficacy against increased development costs and time to market?

Introduction

In developing new digital therapeutics, Pear Therapeutics faces a critical trade-off between pursuing higher efficacy and managing development costs and time to market. This scenario involves balancing the potential for improved patient outcomes against financial and time constraints in a rapidly evolving digital health landscape.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm thinking about Pear's current product portfolio and pipeline. Could you provide an overview of the therapeutic areas we're focusing on and their respective market sizes?

Why it matters: Helps prioritize development efforts based on market potential Expected answer: Focus on mental health, substance use disorders, and chronic conditions Impact: Would influence resource allocation and efficacy targets

• Business Context: Based on our business model, I assume we're looking at prescription digital therapeutics (PDTs). How does our revenue model work - is it primarily through reimbursement, or do we have direct-to-consumer channels?

Why it matters: Affects pricing strategy and go-to-market approach Expected answer: Primarily reimbursement-based with some direct-to-consumer options Impact: Would influence the balance between efficacy and cost considerations

• User Impact: Considering patient adherence is crucial for efficacy, what's our current understanding of user engagement patterns across our products?

Why it matters: Helps identify where increased efficacy might have the most impact Expected answer: Varied engagement levels, with room for improvement in long-term adherence Impact: Could shift focus towards engagement features vs. pure clinical efficacy

• Technical: Given the rapid advancements in AI and machine learning, how flexible is our current tech stack to incorporate these technologies for potentially higher efficacy?

Why it matters: Affects our ability to leverage cutting-edge tech for efficacy gains Expected answer: Moderately flexible, with ongoing efforts to enhance AI capabilities Impact: Might influence the trade-off between immediate development and future-proofing

• Resource: What's our current R&D capacity, and how does it align with our product roadmap?

Why it matters: Determines our ability to pursue higher efficacy without sacrificing other priorities Expected answer: Stretched thin, with multiple projects in development Impact: Could lead to prioritizing certain products for high-efficacy pursuits